Penson, David F. http://orcid.org/0000-0002-2580-2697
Armstrong, Andrew J. http://orcid.org/0000-0001-7012-1754
Concepcion, Raoul S.
Agarwal, Neeraj http://orcid.org/0000-0003-1076-0428
Olsson, Carl A.
Karsh, Lawrence I.
Dunshee, Curtis J.
Duggan, William
Shen, Qi
Sugg, Jennifer
Haas, Gabriel P.
Higano, Celestia S.
Funding for this research was provided by:
Pfizer
Astellas Pharma US
Article History
Received: 26 May 2021
Revised: 17 September 2021
Accepted: 23 September 2021
First Online: 7 October 2021
Change Date: 30 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-021-00477-3
Competing interests
: DFP has no conflicts to disclose. AJA is a paid consultant with Pfizer, Astellas, Janssen, Bayer, AstraZeneca and Merck; AJA receives research funding (to his institution) from Pfizer, Astellas, Janssen, Bayer, Dendreon, Novartis, Genentech/Roche, Merck, BMS, AstraZeneca, Constellation, and BeiGene. NA is a consultant to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. LIK is a consultant to Astellas, AstraZeneca, Aurora Oncology, Bayer, Dendreon, Ferring/Fergene, Genentech, Genomic Health, Janssen, Kiadis, Merck, Pfizer, Urogen, UROGPO, and Vaxiion; LIK is a speaker for Astellas, Astra Zeneca, Bayer, Clovis Oncology, Janssen, Merck, Myovant, Pfizer, and Sesen; LIK is a principle investigator for clinical trials of Astellas, Astra Zeneca, Bayer, Bioxcel, BMS, Dendreon, Exact Sciences, Epizyme, Exelexis, FKD Therapies, Ferring, Genome DX Biosciences, Hinova, Janssen, Merck, Myovant, Pfizer, Tavanta, QED, Urogen, Vaxiion. RSC, CAO, CJD have no conflicts to disclose. WD is an employee of Pfizer and owns company stock. QS is an employee of Pfizer. JS is an employee of Astellas. GPH is an employee of Astellas. CSH receives research funding from Aptevo, Aragon, Astellas, AstraZeneca, Clovis, Dendreon, eFFECTOR Therapeutics, Emergent, Ferring, Genentech, Hoffman-Laroche, Medivation, and Pfizer; CSH is a consultant and member of scientific advisory boards for Astellas, Bayer, Blue Earth Diagnositics, Clovis, Dendreon, Ferring, Hinova, Janssen, Merck, Orion, Pfizer, Tolmar, Carrick Therapeutics, Novartis, Genentech; the spouse of CSH holds stock and was former officer of CTI Biopharma.